Factsheet describing the results of the SEQUOIA trial, a global Phase 3, open label study of zanubrutinib in patients with previously untreated chronic lymphocytic leukemia (CLL).
Slide kit describing the safety and efficacy data of the final analysis of the MAGNOLIA study, a Phase 2, open-label study of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).
Factsheet describing the safety and efficacy data of the final analysis of the MAGNOLIA study, a Phase 2, open-label study of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).
Factsheet summarising the results of the ROSEWOOD trial, a Phase 2 study of zanubrutinib plus obinutuzumab in patients with relapsed/refractory (R/R) follicular lymphoma (FL).
Phase 2 study evaluating the safety of zanubrutinib in patients with B-cell malignancies who have become intolerant of prior ibrutinib and/or acalabrutinib treatment.
